This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Pancreatic cancer is a difficult clinical problem. Oxaliplatin substitutes for cisplatin in this combined modality approach. The toxicity of this new platinum may be less, while its efficacy may be greater in pancreatic cancer. In phase I, the minimum tolerated dose (MTD) will be determined in pancreatic cancer, since the available data is in rectal cancer. In phase 2, the hypothesis is that oxaliplatin + 5-FU is a better drug combination with radiation therapy than gemcitabine+cisplatin, because it is more tolerable and possibly superior in terms of efficacy.
Showing the most recent 10 out of 470 publications